Tyrosine Kinase Inhibitors: all 10,479 studies that test it

Page 76 of 105. Open to participants first (1,915), then studies with results posted, then the rest; newest registration first within each.

• A Study of HMPL-453 in Patients With Advanced Solid MalignanciesStatus unknownNCT03160833Phase 1/2
• Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE)TerminatedNCT03159936Early Phase 1
• NCT Neuro Master Match - N²M² (NOA-20)CompletedNCT03158389Phase 1/2
• A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)CompletedNCT03158103Phase 1
• Bone Metastasis on the Survival of Gefitinib Effective PatientsCompletedNCT03157310Not applicable
• A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung CancerCompletedNCT03155009Phase 2
• Icotinib Combined With SBRT for Patients With Metastatic Non-squamous NSCLC With EGFR MutationStatus unknownNCT03153358Phase 2
• Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)Active, not recruitingNCT03153202Phase 1/2
• Intermittent and Maintenance of Icotinib in Combination With Pemetrexed/Carboplatin Compared With Icotinib Single Drug in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) MutationStatus unknownNCT03151161Phase 2
• Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue SarcomasWithdrawnNCT03149120Phase 2
• QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid TumorsWithdrawnNCT03147976Phase 2
• Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic LeukemiaActive, not recruitingNCT03147612Phase 2
• Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract CancersStatus unknownNCT03144856Phase 2
• Apatinib Combined With Paclitaxol as Second Line Therapy for Advanced Gastric Cancer.Status unknownNCT03144843Phase 2
• An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other MalignanciesTerminatedNCT03144661Phase 1
• A Study To Evaluate ASN002 In Subjects With Atopic DermatitisCompletedNCT03139981Phase 1
• UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib AloneSuspendedNCT03139747Phase 2
• PAZIT Study for Children and Young Adults With Relapsed or Refractory SarcomaCompletedNCT03139331Phase 1
• Effect of Probenecid on Pexidartinib PharmacokineticsCompletedNCT03138759Phase 1
• OMO-1 in Solid MalignanciesTerminatedNCT03138083Phase 1/2
• Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCCCompletedNCT03136627Phase 1/2
• Apatinib and Etoposide as the Maintenance Therapy in Extensive-stage Small Cell Lung Cancer After First-line ChemotherapyStatus unknownNCT03135977Phase 2
• A Study to Evaluate the Effect of Fluconazole and Itraconazole on Erdafitinib Pharmacokinetics in Healthy Adult ParticipantsCompletedNCT03135106Phase 1
• Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITDStatus unknownNCT03135054Phase 2
• Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory LeukemiaActive, not recruitingNCT03132454Phase 1
• Phase I Study of a Selective ALK Inhibitor PLB1003 in Patients With ALK+ NSCLC.Status unknownNCT03130881Phase 1
• Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line)CompletedNCT03130790Phase 2/3
• Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain AmyloidosisWithdrawnNCT03130348Phase 2
• Maintenance Treatment of Apatinib in Nasopharyngeal CarcinomaStatus unknownNCT03130270Phase 2
• Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2CompletedNCT03129828Phase 1/2
• The Efficacy and Safety of Apatinib Monotherapy in Maintenance Treatment of Extensive-stage Small-cell Lung CancerStatus unknownNCT03129698Phase 2
• Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract CancerWithdrawnNCT03129074Phase 2
• Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLLActive, not recruitingNCT03128879Phase 2
• AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR MutationsTerminatedNCT03127449Not applicable
• A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+)Status unknownNCT03126799Phase 2
• A Phase Ib Study of CT053PTSA in Relapsed / Refractory Acute Myeloid Leukemia (AML)TerminatedNCT03125876Phase 1
• Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT03125239Phase 1
• Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung CancerActive, not recruitingNCT03122717Phase 1/2
• Mesylate Apatinib for Stage Ⅳ STS After Failure of ChemotherapyStatus unknownNCT03121846Phase 2
• Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian CancerCompletedNCT03117933Phase 2
• Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and LymphomaActive, not recruitingNCT03117751Phase 2/3
• A Study to Assess Efficacy and Safety of Filgotinib in Ankylosing SpondylitisCompletedNCT03117270Phase 2
• Study of the AL3810 in the Treatment of Advanced Solid TumorCompletedNCT03117101Phase 1
• Apatinib Plus Irinotecan as Second-line Treatment in AGC or EGJAStatus unknownNCT03116555Phase 2
• Dose Finding Study of TNO155 in Adult Patients With Advanced Solid TumorsTerminatedNCT03114319Phase 1
• Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective StudyStatus unknownNCT03110484Phase 2
• Study of Milciclib in Patients With Unresectable/Metastatic Hepatocellular CarcinomaCompletedNCT03109886Phase 2
• Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter TrialWithdrawnNCT03104335Phase 2
• Apatinib for the Elderly Advanced Gastric CancerCompletedNCT03104283Phase 2
• A Study to Assess Efficacy and Safety of Filgotinib in Active Psoriatic ArthritisCompletedNCT03101670Phase 2
• A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung CancerStatus unknownNCT03100955Phase 3
• A Phase I Study of TQ-B3139 on Tolerance and PharmacokineticsStatus unknownNCT03099330Phase 1
• Efficacy and Safety of Sorafenib as Adjuvant and Latter Radiofrequency Ablation for Recurrent Hepatocellular CarcinomaStatus unknownNCT03097848Not applicable
• A Study of Apatinib Plus Tegafur Gimeracil Oteracil in Recurrent/Metastatic Head and Neck CancersStatus unknownNCT03096184Phase 2
• A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)CompletedNCT03096080Phase 1
• CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell CarcinomaStatus unknownNCT03095040Phase 3
• Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone LymphomaTerminatedNCT03093831Phase 2
• Biomarker-based Study in R/M SCCHNActive, not recruitingNCT03088059Phase 2
• Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT03087448Phase 1
• Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast CancerStatus unknownNCT03086785Phase 2
• Pemetrexed Plus Tarceva as Salvage Treatment in EGFR Overexpressed Metastatic Colorectal Cancer Patients Who Were Failed After Standard ChemotherapyCompletedNCT03086538Phase 2
• A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs HerceptinStatus unknownNCT03085368Phase 2/3
• Afatinib in Locally Advanced and Metastatic ChordomaCompletedNCT03083678Phase 2
• A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) MutationsTerminatedNCT03082300Phase 1
• Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal CancerCompletedNCT03081494Phase 1
• Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)Status unknownNCT03080805Phase 3
• Dasatinib Versus Nilotinib for Treatment Naïve Chronic Myeloid LeukemiaTerminatedNCT03079505Phase 3
• A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer PatientsCompletedNCT03075462Phase 1
• Targeted Treatment With Intercalated Radiotherapy in EGFR-mutant IIIA/IIIB NSCLCStatus unknownNCT03074864Phase 2/3
• A Clinical Trial of Apatinib Plus Docetaxel in Locally Advanced or Metastatic Gastric or GEJ AdenocarcinomaStatus unknownNCT03071042Phase 1
• Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell TumorActive, not recruitingNCT03069469Phase 1/2
• A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With MyelofibrosisActive, not recruitingNCT03069326Phase 2
• A Study to Determine the Effect of Food on the Pharmacokinetics of Erdafitinib in Healthy ParticipantsCompletedNCT03066687Phase 1
• Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment.CompletedNCT03066427Phase 2
• Poziotinib in EGFR Exon 20 Mutant Advanced NSCLCTerminatedNCT03066206Phase 2
• A Phase II Study of Apatinib in STS PatientsStatus unknownNCT03064243Phase 2
• A Study of Nintedanib for LymphAngioleioMyomatosis (LAM)CompletedNCT03062943Phase 2
• A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHLStatus unknownNCT03060850Phase 1
• Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)CompletedNCT03059797Phase 2
• A Study Comparing AC0010 and Chemotherapy in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKIWithdrawnNCT03058094Phase 3
• Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung CancerTerminatedNCT03054038Phase 1
• Preliminary Evaluation of Safety and Efficacy by [14C] AC0010 Trail and Subsequent AC0010 TreatmentCompletedNCT03053219Phase 1
• Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung CancerStatus unknownNCT03050411Phase 1
• Bioequivalence Study of Gefitinib Tablets Under Fed ConditionsCompletedNCT03050177Phase 1
• Bioequivalence Study of Gefitinib Tablets Under Fasting ConditionsCompletedNCT03050164Phase 1
• Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid CancerStatus unknownNCT03048877Phase 3
• Clinical Trial of YH25448 in Patients with EGFR Mutation Positive Advanced NSCLCCompletedNCT03046992Phase 1/2
• Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC)Status unknownNCT03046979Phase 2
• Effect of BMS-986165 on the Pharmacokinetics of RosuvastatinCompletedNCT03044873Phase 1
• Study of Regorafenib in Patients With Advanced Myeloid MalignanciesCompletedNCT03042689Phase 1
• A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 StudyWithdrawnNCT03042013Phase 2
• Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid CancersTerminatedNCT03037645Phase 1/2
• Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell CarcinomaWithdrawnNCT03035630Phase 2
• Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJAStatus unknownNCT03030937Phase 2
• Apatinib and Chemotherapy Sequential Treatment With Cervical CancerStatus unknownNCT03029013Not applicable
• A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer PatientsStatus unknownNCT03026881Phase 1
• A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma MultiformeStatus unknownNCT03025893Phase 2/3
• Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid TumorsCompletedNCT03023319Phase 1
• Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT03021460Phase 1
• A Phase I Study of TQ-B3101 on Tolerance and PharmacokineticsStatus unknownNCT03019276Phase 1

← Tyrosine Kinase Inhibitors overview